High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
oleh: Andres Moreira-Soto, Andres Moreira-Soto, Mauricio Arguedas, Hebleen Brenes, Willem Buján, Willem Buján, Eugenia Corrales-Aguilar, Cecilia Díaz, Cecilia Díaz, Ann Echeverri, Marietta Flores-Díaz, Aarón Gómez, Andrés Hernández, María Herrera, Guillermo León, Román Macaya, Arne Kühne, José Arturo Molina-Mora, Javier Mora, Alfredo Sanabria, Andrés Sánchez, Laura Sánchez, Álvaro Segura, Eduardo Segura, Daniela Solano, Claudio Soto, Jennifer L. Stynoski, Mariángela Vargas, Mauren Villalta, Chantal B. E. M. Reusken, Christian Drosten, José María Gutiérrez, Alberto Alape-Girón, Alberto Alape-Girón, Jan Felix Drexler, Jan Felix Drexler
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2021-09-01 |
Deskripsi
SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078 μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.